NASDAQ: VIRVir Biotechnology Inc Stock
$7.63-0.41 (-5.1%)
Updated Apr 25, 2024
VIR Price
$7.63
Fair Value Price
N/A
Market Cap
$1.03B
52 Week Low
$7.61
52 Week High
$27.48
P/E
-1.66x
P/B
0.65x
P/S
15.66x
PEG
N/A
Dividend Yield
N/A
Revenue
$86.18M
Earnings
-$615.06M
Gross Margin
96.8%
Operating Margin
-728.87%
Profit Margin
-713.7%
Debt to Equity
0.21
Operating Cash Flow
-$779M
Beta
0.5
Next Earnings
May 29, 2024
Ex-Dividend
N/A
Next Dividend
N/A
VIR Overview
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how VIR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VIR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
VIR is good value based on its book value relative to its share price (0.65x), compared to the US Biotechnology industry average (5.8x)
P/B vs Industry Valuation
VIR is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more VIR due diligence checks available for Premium users.
Be the first to know about important VIR news, forecast changes, insider trades & much more!
VIR News
Valuation
VIR fair value
Fair Value of VIR stock based on Discounted Cash Flow (DCF)
Price
$7.63
Fair Value
-$0.08
Undervalued by
9,501.30%
VIR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
VIR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.66x
Industry
15.41x
Market
40.97x
VIR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.65x
Industry
5.8x
VIR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
VIR's financial health
Profit margin
Revenue
$16.8M
Net Income
-$116.0M
Profit Margin
-690.9%
VIR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
VIR's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.9B
Liabilities
$328.8M
Debt to equity
0.21
VIR's short-term assets ($1.59B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VIR's short-term assets ($1.59B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VIR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
VIR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$107.9M
Investing
-$104.8M
Financing
$1.7M
VIR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
VIR vs Biotech Stocks
Vir Biotechnology Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.